Health Condition 1: L439- Lichen planus, unspecified
Conditions
Interventions
Intervention1: clobetasol in cutaneous lichen planus: Patients clinically diagnosed with cutaneous lichen planus will be enrolled. Participants will be randomly assigned to one of two treatment groups
Sponsors
Dr Keerthana K S
Eligibility
Inclusion criteria
Inclusion criteria: Adults aged 18 65 years. Clinically confirmed cases of cutaneous lichen planus. Patients willing to participate and provide written informed consent. Patients willing to comply with follow-up visits and study protocol.
Exclusion criteria
Exclusion criteria: Pregnant and lactating women. Patients with mucosal, nail, or scalp lichen planus without cutaneous lesions. Patients with uncontrolled systemic illnesses (diabetes, hypertension, active tuberculosis, or chronic infections). Known hypersensitivity to clobetasol or tofacitinib. Patients who will have received systemic immunosuppressants or topical steroids in the last 4 weeks. Patients with hepatic or renal dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of topical tofacitinib vs topical clobetasol in patients with cutaneous lichen planusTimepoint: week 0,4,8,12 | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the safety & tolerability of the two treatment groups. To evaluate patient-reported outcomes such as pruritus reduction & quality of life improvement. To assess recurrence rates after treatment completion Timepoint: week 0,4, 8, 12 | — |
Countries
India
Contacts
Public ContactDr Keerthana K S
Chettinad Hospital and research institute
Outcome results
None listed